Please note, these are the actual video-recorded proceedings from the live CME event and may include the use of trade names and other raw, unedited content. - ppt download
NCCP Regimen 00780 Bortezomib, Lenalidomide and Dexamethasone (RVD-Lite) Induction Therapy Myeloma
NCCP Regimen 00781 Bortezomib and Lenalidomide (RVD-Lite) Consolidation Therapy Myeloma
Daratumumab in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Mye
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. - Abstract - Europe PMC
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant‐ineligible multiple myeloma - O'Donnell - 2018 - British Journal of Haematology - Wiley Online Library
Clinical Outcomes of Non-Traditional Lenalidomide, Bortezomib, and Dexamethasone Regimens in Multiple Myeloma - ScienceDirect
BORTDEXALENA(LD) Regimen
Role of Anti–CD38 Antibody Therapy in Induction and Maintenance in Newly Diagnosed Multiple Myeloma: How to Adopt in Clinical Practice
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant‐ineligible multiple myeloma - O'Donnell - 2018 - British Journal of Haematology - Wiley Online Library
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. - Abstract - Europe PMC
When do you consider the use of RVD lite?
Frontiers | Approaches and Challenges in the Management of Multiple Myeloma in the Very Old: Future Treatment Prospects
Multiple Myeloma Clinical Trials - Completed
December 5 – 9, 2014 San Francisco, CA - ppt download
Multiple Myeloma Chemotherapy-VCD-Lite, RVD-Lite - PeopleBeatingCancer
Triplet or Quadruplet Therapy in Transplant-Ineligible NDMM
Up-front therapy for older patients at standard risk | Research To Practice
Optimizing Frontline Care for Older Patients With Multiple Myeloma (Transcript)
Tanya Wildes MD on Twitter: "Noopur Raje: RVD-lite yields ORR 90% & 1year PFS >90%. Very promising for our most vulnerable older MM patients! #ASH16 #GeriOnc #mmsm https://t.co/nPIYokepSu" / Twitter
Induction Therapy and MM
Designing a Therapy Sequence for the Treatment of Multiple Myeloma
Multiple Myeloma Hub on Twitter: "CONGRESS | #ASCO21 | How to treat high-risk NDMM? Several studies are exploring if BCMA-directed therapy will improve, at last, the prognosis of these patients. Until then,
